AMRN Latest Press Releases

-- October 28, 2026 --

Amarin Reports 2026 Third Quarter Financial Results, Achieves Positive Net Income Globe Newswire 7:00 AM

-- October 25, 2026 --

Amarin Provides Update on University of Leeds Sponsored Phase 3 EPA for Metastasis Trial 2 (EMT2) Evaluating VAZKEPA/VASCEPA (icosapent ethyl) Capsules on Top of Standard of Care Treatment in Patients Undergoing Liver Resection for Colorectal Cancer Liver Metastases (CRCLM) Globe Newswire 8:11 AM

-- October 21, 2026 --

Amarin to Report Third Quarter 2026 Financial Results and Host Conference Call on October 28, 2026 Globe Newswire 8:00 AM

-- August 31, 2026 --

Amarin Highlights New REDUCE-IT and Mechanistic Data Presented at European Society of Cardiology (ESC) Congress 2026 Globe Newswire 8:15 AM

-- August 28, 2026 --

New REDUCE-IT Legacy Analysis Presented at European Society of Cardiology (ESC) Congress 2026 Suggests Persistent Cardiovascular Benefit Following Icosapent Ethyl Treatment Cessation in Adherent Patients Globe Newswire 8:15 AM

-- August 24, 2026 --

New Analyses from REDUCE-IT and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2026 Globe Newswire 8:15 AM

-- July 29, 2026 --

Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence Globe Newswire 7:00 AM

-- July 15, 2026 --

Amarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026 Globe Newswire 8:00 AM

-- June 30, 2026 --

Amarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape Globe Newswire 4:15 PM

Market Data Delayed 15 Minutes